TCGA-55-8620-01A-11R-2403-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- PANCREAS_BETA_CELLS+0.330
- G2M_CHECKPOINT+0.310
- SPERMATOGENESIS+0.270
- MYC_TARGETS_V2+0.200
- DNA_REPAIR+0.100
- MITOTIC_SPINDLE+0.080
- HEDGEHOG_SIGNALING+0.060
- BILE_ACID_METABOLISM+0.050
- OXIDATIVE_PHOSPHORYLATION+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- TNFA_SIGNALING_VIA_NFKB-0.550
- TGF_BETA_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.460
- ANGIOGENESIS-0.440
- APOPTOSIS-0.420
- APICAL_SURFACE-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- P53_PATHWAY-0.400
- INTERFERON_ALPHA_RESPONSE-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 80680b8f-eec8-4b02-95c4-f133af61943a | — | — | 0.913 |
| 2 | SRR13780269 | — | cohortSC | 0.906 |
| 3 | SRR8526719 | — | cohortMD1 | 0.903 |
| 4 | BS_W9AT0MR7 | medulloblastoma | — | 0.900 |
| 5 | TCGA-86-8358-01A-11R-2326-07 | — | cohortA3 | 0.896 |
| 6 | BS_ERWT0ZWE | medulloblastoma | — | 0.896 |
| 7 | BS_ZXYDSBM9 | medulloblastoma | — | 0.895 |
| 8 | BS_GE2RVZE6 | medulloblastoma | — | 0.891 |
| 9 | BS_V9HVBBDW | medulloblastoma | — | 0.888 |
| 10 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |